Napo Pharmaceuticals-backed pet medicine developer Jaguar Animal Health is set to raise $40.4m if it floats at the middle of its range.
Jaguar Animal Health, a US-based developer of gastrointestinal products for animals, has announced the terms for its forthcoming initial public offering, and plans to offer 5 million shares priced at $7-$9.
Were the company to float at the middle of the range, it would raise $40.4m.
The company is working on treatments for diarrhea in dogs. The proceeds will be used for further clinical trials and manufacturing and commercialisation costs.
Jaguar’s parent company Napo Pharmaceuticals is the majority shareholder in…
